Floatz logo

Brigatinib

Progressive Disease

University of California, San FranciscoSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Progressive Disease cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Jonsson Comprehensive Cancer Center
Phase 2B
Fludarabine
Jonsson Comprehensive Cancer Center
Phase 2B
Axicabtagene Ciloleucel
Jonsson Comprehensive Cancer Center
Phase 2CCC
Anakinra
Jonsson Comprehensive Cancer Center
Phase 2CCC
Autologous Humanized Anti-Cd22 Chimeric Antigen Receptor T Cells
M.D. Anderson Cancer Center
Phase 1/2CCC

View all 16 →

Same molecule, other indications

Brigatinib is also rated in:

cancerDormant
B
Indicative ·
63 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →